Physician profile
Philippe F Backeljauw
NPI 1770511883
$632,427.20
in general payments reported to CMS, 2019-2025
20 companies · $180K in 2025
The $180K reported for 2025 was more than what 99% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $6,803 · 2021: $25K · 2022: $151K · 2023: $128K · 2024: $114K · 2025: $180K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $229K · Consulting Fee: $100K · Travel and Lodging: $81K · Food and Beverage: $7,232 · Honoraria: $5,885 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $229,005.25 |
| Consulting Fee | $99,711.36 |
| Travel and Lodging | $80,992.27 |
| Food and Beverage | $7,231.55 |
| Honoraria | $5,885.00 |
| Education | $284.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $245,196.02 | 2021-2025 | Voxzogo 1.2mg, Vimizim |
| Ascendis Pharma Endocrinology INC | $174,157.03 | 2022-2025 | Skytrofa |
| Novo Nordisk Health Care Ag | $97,846.40 | 2019-2024 | Norditropin, Sogroya |
| Novo Nordisk INC | $30,377.92 | 2019-2025 | Sogroya, Norditropin |
| Tolmar Pharmaceuticals, INC. | $23,352.53 | 2022 | |
| Eton Pharmaceuticals, INC. | $18,155.14 | 2025 | Alkindi, Increlex, Khindivi |
| Ipsen Biopharmaceuticals, INC | $11,710.00 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $5,967.27 | 2019 | |
| Tolmar, INC. | $5,927.56 | 2023-2025 | Fensolvi |
| Upsher-Smith Laboratories LLC | $4,675.00 | 2023-2024 | |
| Pfizer INC. | $4,522.08 | 2020-2025 | |
| Ipsen Innovation | $3,010.00 | 2021 | |
| Abbvie INC. | $1,687.50 | 2020 | |
| Vistapharm, INC. | $1,540.00 | 2021 | |
| Sandoz INC. | $1,511.80 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $1,500.00 | 2024 | |
| Ipsen Biopharm Limited | $1,155.00 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $122.07 | 2021 | |
| Abbott Laboratories | $13.88 | 2023 | Freestyle Libre 3 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Backeljauw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.